Abstract
Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have been implicated in angiogenesis, tumor growth and invasion, apoptosis resistance and suppression of anti-tumor immunity. Recent studies also revealed that PGE2 signaling may confer cells resistant to targeted growth factor receptor therapy by cross-activation of the receptor signaling pathway downstream components. Pre-clinical studies in animal tumor models have shown tumor reduction when animals are treated with COX-2 inhibitors and have demonstrated promising results when COX-2 inhibitors were combined with chemotherapeutic drugs. Based on these observations several ongoing clinical trials are currently evaluating COX-2 inhibitors as adjuvants with chemotherapy or radiation therapy in patients with advanced non-small cell lung cancer. Further understanding of the mechanisms of COX-2 in tumorigenesis and its interaction with other cellular pathways may highlight the new diagnostic, prognostic and therapeutic markers and facilitate future development of targeted strategies for lung cancer treatment and prevention.
Keywords: Cyclooxygenase, COX inhibitors, COX-2, lung cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Volume: 6 Issue: 3
Author(s): Kostyantyn Krysan, Karen L. Reckamp, Sherven Sharma and Steven M. Dubinett
Affiliation:
Keywords: Cyclooxygenase, COX inhibitors, COX-2, lung cancer
Abstract: Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have been implicated in angiogenesis, tumor growth and invasion, apoptosis resistance and suppression of anti-tumor immunity. Recent studies also revealed that PGE2 signaling may confer cells resistant to targeted growth factor receptor therapy by cross-activation of the receptor signaling pathway downstream components. Pre-clinical studies in animal tumor models have shown tumor reduction when animals are treated with COX-2 inhibitors and have demonstrated promising results when COX-2 inhibitors were combined with chemotherapeutic drugs. Based on these observations several ongoing clinical trials are currently evaluating COX-2 inhibitors as adjuvants with chemotherapy or radiation therapy in patients with advanced non-small cell lung cancer. Further understanding of the mechanisms of COX-2 in tumorigenesis and its interaction with other cellular pathways may highlight the new diagnostic, prognostic and therapeutic markers and facilitate future development of targeted strategies for lung cancer treatment and prevention.
Export Options
About this article
Cite this article as:
Krysan Kostyantyn, Reckamp L. Karen, Sharma Sherven and Dubinett M. Steven, The Potential and Rationale for COX-2 Inhibitors in Lung Cancer, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (3) . https://dx.doi.org/10.2174/187152006776930882
DOI https://dx.doi.org/10.2174/187152006776930882 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Synthesis of Coumarin linked Naphthalimide Conjugates as Potential Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery Nucleosides with Modified Sugar Ring: Synthesis and Biological Activities
Current Organic Chemistry Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial
Reviews on Recent Clinical Trials Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Quantitative Proteomics Profiling of RKO and HT29 Cell Lines by iTRAQ Coupled LC-MS/MS
Current Proteomics High Throughput Screening for Protein Kinase Inhibitors
Combinatorial Chemistry & High Throughput Screening Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic: Synthetic, Natural and Related Compounds: New Approach to Chronic Diseases Studies)
Current Topics in Medicinal Chemistry Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Editorial [Hot Topic: Prospective Clinical Role for Anticancer Garlic Organosulfur Compounds (Guest Editor: Hassan T. Hassan)]
Anti-Cancer Agents in Medicinal Chemistry Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Silver Nanomaterials in Contemporary Molecular Physiology Research
Current Medicinal Chemistry